These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1429424)

  • 41. Fluoxetine inhibits desipramine metabolism.
    Wilens TE; Biederman J; Baldessarini RJ; McDermott SP; Puopolo PR; Flood JG
    Arch Gen Psychiatry; 1992 Sep; 49(9):752. PubMed ID: 1514882
    [No Abstract]   [Full Text] [Related]  

  • 42. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder.
    Higgins ES
    J Fam Pract; 1999 Jan; 48(1):15-20. PubMed ID: 9934377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Loss of appetite and weight associated with the monoamine oxidase inhibitor isocarboxazid.
    Davidson J; Turnbull C
    J Clin Psychopharmacol; 1982 Aug; 2(4):263-6. PubMed ID: 7119133
    [No Abstract]   [Full Text] [Related]  

  • 44. Treatment of outpatients with desipramine.
    Rosenbaum JF
    J Clin Psychiatry; 1984 Oct; 45(10 Pt 2):17-22. PubMed ID: 6384206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MBD children--variability in developmental patterns or growth inhibitory effect of stimulants?
    Kaffman M; Sher A; Bar-Sinai N
    Isr Ann Psychiatr Relat Discip; 1979 Mar; 17(1):58-66. PubMed ID: 287660
    [No Abstract]   [Full Text] [Related]  

  • 46. Evidence for in vivo methylation of the secondary amino antidepressant desipramine to imipramine in humans.
    Narasimhachari N; Saady JJ; Joseph A; Ettigi P; Friedel RO
    J Clin Psychopharmacol; 1982 Dec; 2(6):413-6. PubMed ID: 7174866
    [No Abstract]   [Full Text] [Related]  

  • 47. The myth of attention deficit-hyperactivity disorder: symptoms resulting from multiple causes.
    Weinberg WA; Brumback RA
    J Child Neurol; 1992 Oct; 7(4):431-45; discussion 446-61. PubMed ID: 1469255
    [No Abstract]   [Full Text] [Related]  

  • 48. Sudden death in children receiving Norpramin: a review of three reported cases and commentary.
    Riddle MA; Nelson JC; Kleinman CS; Rasmusson A; Leckman JF; King RA; Cohen DJ
    J Am Acad Child Adolesc Psychiatry; 1991 Jan; 30(1):104-8. PubMed ID: 2005044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Steady-state plasma imipramine levels in prepubertal depressed children.
    Weller EB; Weller RA; Preskorn SH; Glotzbach R
    Am J Psychiatry; 1982 Apr; 139(4):506-8. PubMed ID: 7065300
    [No Abstract]   [Full Text] [Related]  

  • 50. Pseudodepression in hyponatremia.
    Boczkowski JA; Levine EG
    J Nerv Ment Dis; 1991 Aug; 179(8):508-10. PubMed ID: 1741820
    [No Abstract]   [Full Text] [Related]  

  • 51. Fluoxetine in adults with residual attention deficit disorder and hypersomnolence.
    Sabalesky DA
    J Neuropsychiatry Clin Neurosci; 1990; 2(4):463-4. PubMed ID: 2136402
    [No Abstract]   [Full Text] [Related]  

  • 52. Cardiovascular effects of desipramine in children and adolescents with attention deficit disorder.
    Biederman J; Gastfriend D; Jellinek MS; Goldblatt A
    J Pediatr; 1985 Jun; 106(6):1017-20. PubMed ID: 3998940
    [No Abstract]   [Full Text] [Related]  

  • 53. Adult attention deficit hyperactivity disorder and desipramine.
    Magee R; Maier D; Reesal RT
    Can J Psychiatry; 1992 Mar; 37(2):148-9. PubMed ID: 1562962
    [No Abstract]   [Full Text] [Related]  

  • 54. The safety of desipramine.
    Werry JS
    J Am Acad Child Adolesc Psychiatry; 1994 May; 33(4):588-91. PubMed ID: 8005913
    [No Abstract]   [Full Text] [Related]  

  • 55. Chronic imipramine treatment and weight gain.
    Fernstrom MH; Krowinski RL; Kupfer DJ
    Psychiatry Res; 1986 Apr; 17(4):269-73. PubMed ID: 3714910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Depression in childhood: a biopsychosocial perspective.
    Lewis M; Lewis DO
    Am J Psychother; 1981 Jul; 35(3):323-9. PubMed ID: 6117207
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolism, anticholinergic effects, and therapeutic outcome of desmethylimipramine in depressive illness.
    Watt DC; Crammer JL; Elkes A
    Psychol Med; 1972 Nov; 2(4):397-405. PubMed ID: 4571142
    [No Abstract]   [Full Text] [Related]  

  • 58. Potential mechanism of desipramine-related sudden death in children.
    Wagner KD; Fershtman M
    Psychosomatics; 1993; 34(1):80-3. PubMed ID: 8426895
    [No Abstract]   [Full Text] [Related]  

  • 59. Lack of weight gain under desipramine.
    Stern SL; Cooper TB; Johnson MH; Jones BA; Nelson LD; Smeltzer DJ
    Biol Psychiatry; 1987 Jun; 22(6):796-7. PubMed ID: 3593822
    [No Abstract]   [Full Text] [Related]  

  • 60. The diagnosis and treatment of hidden depression.
    Abroms GM
    Psychiatr Q; 1981; 53(4):235-41. PubMed ID: 7330133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.